HEMOPATCH

As an easy-to-use sealing haemostat, surgeons rely on HEMOPATCH to control intraoperative bleeding and post-operative leakage. Surgeons prefer HEMOPATCH for its strong tissue adherence and flexibility, as well as its handling and ease of use.^1,2

Image showing the benefits of using Hemopatch - less days in ICU and hospital, less complications equals less cost

Improving Outcomes

Surgeons have few tools to prevent post-operative pancreatic fistulas. HEMOPATCH demonstrated significant cost savings and improved patient outcomes.⁶

Image of two gloved hands holding Hemopatch product

Fast and Effective Sealing and Haemostasis

92% of surgeons rated HEMOPATCH as highly satisfactory for its ease of use, handling, flexibility/pliability and tissue adherence characteristics in open and laparoscopic procedures. Successful haemostasis after two minutes of approximation occurred in 93% of patients.^1,2

Mechanism of Action

When you apply HEMOPATCH Sealing Haemostat directly to moist tissue, two processes combine to seal the surface and induce haemostasis.²

Additional Product Benefits

Strong adherence to the tissue surface

HEMOPATCH rapidly adheres to applied tissue due to the electrophilic cross-linking action of NHS-PEG. The patch provides mechanical structure to support friable tissue.²

Designed for utmost flexibility

Soft, thin and flexible collagen pad allows easy handling and preparation for MIS applications. No preparation or pre-moistening required.^1,2

Reduce post-operative complications

HEMOPATCH may decrease post-operative pancreatic fistulas, CSF leakage, and the number of transfusions and revisions in cardiac surgery as compared to the standard of care. Reducing these post-operative complications results in substantial cost savings.^3,4,5

See References

Ulrich, et al. Intra-operative use of HEMOPATCH: Interim results of a nationwide European survey of surgeons. Surgical Technology International. 2016;28:19-28.
Instructions for use Hemopatch Sealing Hemostat BE-30-03-130 (Rev. 2018/12/12).
Serradilla, Martin & M. Ramirez, Cost-Benefit Analysis: HEMOPATCH vs. Standard of Care in the Incidence of Postoperative Pancreatic Fistula in a Observational Study. Am J Biomed Sci & Res. (2019) 1:11-19.
Schebesch K, Brawanski A (February 04, 2019) Clinical Experience with Hemopatch® as a Dural Sealant in Cranial Neurosurgery. Cureus 11(2): e4013. DOI 10.7759/cureus.4013.
Shelly Ikeme, Luca Weltert, Kevin M. Lewis, Gerhard Bothma, Daniela Cianciulli, Nicole Pay, Josh Epstein & Erik Kuntze (2017): Cost-effectiveness analysis of a sealing hemostat patch (HEMOPATCH) vs standard of care in cardiac surgery, Journal of Medical Economics, DOI: 10.1080/13696998.2017.1400977.
Ramirez MG, Mario S, Ramirez Manuel A. Use Of PEG-Coated Collagen Hemostatic Sealant (HS) in Pancreatoduodenectomy (PD) Surgery: Incidence of Postoperative Pancreatic Fistula (POPF) and Cost-Benefit Analysis in a Retrospective Study.

Products

Programmes

Specialties